10 Biggest Price Target Changes For Monday
UBS lifted the price target on Pfizer Inc. (NYSE: PFE) from $52 to $60. Pfizer shares rose 1.5% to $53.56 in pre-market trading.
RBC Capital Downgrades IGM Biosciences to Sector Perform, Lowers Price Target to $51
RBC Capital analyst Brian Abrahams downgrades IGM Biosciences (NASDAQ:IGMS) from Outperform to Sector Perform and lowers the price target from $90 to $51.
64 Stocks Moving In Friday’s Mid-Day Session
Gainers
Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the estimated price range of $4-$6, for raising gross proceeds of $10 million.
RBC Capital Maintains Outperform on IGM Biosciences, Lowers Price Target to $90
RBC Capital analyst Brian Abrahams maintains IGM Biosciences (NASDAQ:IGMS) with a Outperform and lowers the price target from $110 to $90.
IGM Biosciences Q3 EPS $(1.32) Down From $(0.66) YoY
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.32) per share. This is a 100 percent decrease over losses of $(0.66) per share from the same period last year.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
IGM Biosciences Reports Formation Of 2 Business Units: IGM Infectious Diseases, IGM Autoimmunity And Inflammation
IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and